AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...

Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...

Investing.com-- Australian biopharmaceutical giant CSL Ltd (ASX: CSL) reported a rise in half-year net profit, driven ...

CSL (ASX:CSL) has reported a net profit after tax of $2.01 billion for the six months to the ned of December 2024, up 7 per ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

PREVIOUS investigations 1–13 have proved conclusively the solid protection afforded by Enders's live measles-virus vaccine given alone or in combination with human immune globulin. The pattern ...

CSL’s vaccine division is suffering as Americans turn away from flu vaccinations, with a “very severe” influenza season ...

Iran's National Institute of Genetic Engineering and Biotechnology (NIGEB) has developed an anti-cancer vaccine that will be ...

VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

By Christine Chen (Reuters) -Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were ...

Sales of CSL's flu vaccines were down by double digits in the first half amid a fall in immunisation rates since the COVID-19 ...